Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia-Reference-Cited by-同舟云学术

Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia

Published:2013-04 Issue:4 Volume:189 Page:1421-1426
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Elhilali Mostafa M.¹,Pommerville Peter²,Yocum Richard C.³,Merchant Rosemina³,Roehrborn Claus G.⁴,Denmeade Samuel R.⁵

Affiliation:

1. Department of Surgery, McGill University, Montreal, Quebec, Canada

2. Can-Med Clinical Research, Victoria, British Columbia, Canada

3. Sophiris Bio Corp., La Jolla, California

4. Department of Urology, UT Southwestern Medical Center, Dallas, Texas

5. Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, Baltimore, Maryland

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference16 articles.

1. Benign prostatic hyperplasia;Wei,2007

2. Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners;Roehrborn;Prostate Cancer Prostatic Dis,2006

3. Prostate Enlargement: Benign Prostatic Hyperplasia,2006

4. The clinical benefits of dutasteride treatment for LUTS and BPH;Roehrborn;Rev Urol,2004

5. Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options;Sandhu;Drugs Aging,2005

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early investigational agents for the treatment of benign prostatic hyperplasia’;Expert Opinion on Investigational Drugs;2024-03-04

2. Evaluating the Impact of Benign Prostatic Hyperplasia Surgical Treatments on Sexual Health;Biomedicines;2024-01-05

3. Minimal-invasive Therapie: Wie ist der Stand im Jahre 2021 – was kommt, was geht;Aktuelle Urologie;2022-03-01

4. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy;Acta Biomaterialia;2022-03

5. Remodelling of the tumour microenvironment by the kallikrein-related peptidases;Nature Reviews Cancer;2022-01-31